TTY Biopharm (4105) reported revenue of NT$727.8 million for Oct 2026, +36.5% year on year and -20.2% from the previous month. Revenue for Jan–Oct 2026 was NT$5.87 billion (+10.3% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 11 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$727.8 million | +36.5% | -20.2% |
| Sep 2026 | NT$911.4 million | +3.6% | +73.3% |
| Aug 2026 | NT$525.9 million | +14.9% | -2.1% |
| Jul 2026 | NT$537 million | +11.3% | -13.0% |
| Jun 2026 | NT$617.1 million | +15.3% | +19.1% |
| May 2026 | NT$518.4 million | -3.6% | +0.0% |
| Apr 2026 | NT$518.2 million | +17.9% | -13.6% |
| Mar 2026 | NT$599.7 million | +5.8% | +66.8% |
| Feb 2026 | NT$359.6 million | -12.1% | -35.9% |
| Jan 2026 | NT$561.1 million | +16.2% | -12.5% |
| Dec 2025 | NT$641.5 million | +3.1% | +31.7% |
| Nov 2025 | NT$487.3 million | +7.0% | -8.6% |
| Oct 2025 | NT$533.3 million | -16.0% | -39.4% |
| Sep 2025 | NT$879.5 million | +45.1% | +92.1% |
| Aug 2025 | NT$457.9 million | +3.2% | -5.1% |
| Jul 2025 | NT$482.6 million | -0.2% | -9.8% |
| Jun 2025 | NT$535.3 million | +13.0% | -0.4% |
| May 2025 | NT$537.7 million | +21.0% | +22.4% |
| Apr 2025 | NT$439.4 million | -3.8% | -22.5% |
| Mar 2025 | NT$567 million | +42.6% | +38.6% |
| Feb 2025 | NT$409 million | +49.0% | -15.3% |
| Jan 2025 | NT$483 million | -19.7% | -22.3% |
| Dec 2024 | NT$622 million | +22.4% | +36.6% |
| Nov 2024 | NT$455.2 million | -6.5% | -28.3% |
| Oct 2024 | NT$634.9 million | -2.2% | +4.8% |
Jan–Oct 2026 cumulative: NT$5.87 billion (+10.3% YoY)
Other Biotech & Medical companies
Compare with peers: TTY Biopharm vs PEC / TTY Biopharm vs Lotus Pharm / TTY Biopharm vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16